Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ATI-2138
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Study Highlights ATI-2138 As Selective ITK, JAK3 Inhibitor
Details : ATI-2138 is a novel investigational covalent inhibitor of ITK and JAK3 in development for the treatment of autoimmune and inflammatory diseases, like atopic dermatitis.
Product Name : ATI-2138
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 12, 2025
Lead Product(s) : ATI-2138
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bosakitug
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Vivo Capital
Deal Size : $80.0 million
Deal Type : Private Placement
Aclaris Therapeutics Announces $80 Million Private Placement
Details : The company will use the proceeds to fund the research and development of its pipeline, including BSI-045B (bosakitug), a humanized monoclonal antibody targeting thymic stromal lymphopoietin.
Product Name : BSI-045B
Product Type : Antibody
Upfront Cash : Undisclosed
November 18, 2024
Lead Product(s) : Bosakitug
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Vivo Capital
Deal Size : $80.0 million
Deal Type : Private Placement
Lead Product(s) : ATI-1777
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aclaris Announces Top-Line Results from Phase 2b Trial of ATI-1777 for Dermatitis
Details : ATI-1777 is an investigational topical soft JAK 1/3 inhibitor, small molecule drug. It is under phase 2 clinical development for the treatment of mild to severe atopic dermatitis.
Product Name : ATI-1777
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 01, 2024
Lead Product(s) : ATI-1777
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2138
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aclaris Doses First Patient in Phase 2a Trial of ATI-2138 for Atopic Dermatitis
Details : ATI-2138 is an investigational oral covalent inhibitor of ITK, and JAK3. Currently, it is being evaluated for the treatment of Moderate to Severe Atopic Dermatitis.
Product Name : ATI-2138
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2024
Lead Product(s) : ATI-2138
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baricitinib
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Eli Lilly
Deal Size : $31.5 million
Deal Type : Licensing Agreement
Aclaris Sells OLUMIANT® Royalties to OMERS for Up to $315M
Details : OLUMIANT (baricitinib) is the first and only JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring various degrees of oxygen support.
Product Name : Olumiant
Product Type : Other Small Molecule
Upfront Cash : $26.5 million
July 16, 2024
Lead Product(s) : Baricitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Eli Lilly
Deal Size : $31.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Zunsemetinib,Methotrexate
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-450 (zunsemetinib) is an investigational oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor for the treatment of Moderate to Severe Rheumatoid Arthritis.
Product Name : ATI-450
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 13, 2023
Lead Product(s) : Zunsemetinib,Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2138
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics’ Phase I MAD Study of ATI-2138
Details : ATI-2138 is an investigational oral compound being developed for the treatment of autoimmune diseases. It inhibits both T-cell and cytokine receptors which may potentially treat T-cell mediated autoimmune diseases.
Product Name : ATI-2138
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2023
Lead Product(s) : ATI-2138
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2138
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-2138 is an investigational oral covalent ITK/JAK3 inhibitor that is being developed as a potential therapeutic option across a variety of T cell-mediated diseases.
Product Name : ATI-2138
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 18, 2023
Lead Product(s) : ATI-2138
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zunsemetinib,Methotrexate
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-450 (zunsemetinib) is an investigational oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor for the treatment of Moderate to Severe Rheumatoid Arthritis.
Product Name : ATI-450
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 13, 2023
Lead Product(s) : Zunsemetinib,Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zunsemetinib
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-450 (zunsemetinib) is an investigational oral mitogen-activated protein kinase-activated protein kinase 2 inhibitor. This mechanism potentially leads to the inhibition of inflammatory signals. It is being developed for rheumatoid arthritis and psoria...
Product Name : ATI-450
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2023
Lead Product(s) : Zunsemetinib
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable